Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar

A biosimilar product needs to demonstrate biosimilarity to the originator reference product, and the quality profile of the latter should be monitored throughout the period of the biosimilar's development to match the quality attributes of the 2 products that relate to efficacy and safety. For...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seokkyun, Song, Jinsu, Park, Seungkyu, Ham, Sunyoung, Paek, Kyungyeol, Kang, Minjung, Chae, Yunjung, Seo, Heewon, Kim, Hyung-Chan, Flores, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419076/
https://www.ncbi.nlm.nih.gov/pubmed/28296619
http://dx.doi.org/10.1080/19420862.2017.1305530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419076/
https://www.ncbi.nlm.nih.gov/pubmed/28296619
http://dx.doi.org/10.1080/19420862.2017.1305530

Ejemplares similares